NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
15 trialsNCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT04996823 2025-12-04
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06962787 2025-11-17
A Study of BL-B01D1+TKIĀ±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT05969496 2025-04-04
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06889649 2025-03-21
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Peking University First Hospital
Phase 2 Recruiting
NCT05808608 2025-01-27
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
West China Hospital
Phase 1/2 Recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT06211114 2024-11-26
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05420220 2024-05-01
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Recruiting
NCT05817903 2023-05-08
AxIn
Consorzio Oncotech
Phase 2 Recruiting